Scientific and regulatory support for Premarket Tobacco Product Applications
The Premarket Tobacco Product Application (PMTA) pathway is administered by the USFDA’s Center for Tobacco Products (CTP). It applies to new tobacco products seeking an FDA marketing order under the applicable provisions of the Federal Food, Drug, and Cosmetic Act.
PMTA and TPMF support by RIAR Consulting
For manufacturers of nicotine pouches, electronic nicotine delivery systems (ENDS) and other applicable tobacco products, PMTA preparation requires comprehensive product, manufacturing, scientific and regulatory documentation.
RIAR Consulting provides specialised PMTA and Tobacco Product Master File (TPMF) support to companies preparing regulatory submissions for the US market.
Why choose RIAR Consulting?
We don’t just prepare submissions. We build defensible regulatory strategies aligned with FDA expectations.
- Deep FDA CTP regulatory expertise
- Science-driven, compliance-focused approach
- Customized PMTA strategies
- End-to-end regulatory support
- Global life sciences and regulatory consulting experience
Approach
Assess
Understand your product, available data, and regulatory gaps through a comprehensive PMTA risk assessment.
Plan
Develop a tailored PMTA strategy aligned with FDA CTP expectations, timelines, and product-specific requirements.
Execute
Compile, review, and submit a complete, high-quality PMTA dossier, ensuring scientific rigor and regulatory compliance.
Support
Manage FDA interactions, including information requests, deficiency letters, and post-submission communications.
Monitor
Track developments, FDA guidance updates and submission status to ensure continued alignment and timely responses.
Sustain
Provide post-market compliance and lifecycle management support to maintain authorisation and long-term market success.
Our PMTA consulting services
RIAR works with companies to organise their scientific and technical information into structured regulatory documentation aligned with applicable PMTA requirements.
- 01
PMTA regulatory strategy
- Assessment of product eligibility and applicable regulatory requirements
- PMTA pathway assessment
- Regulatory gap assessment
- Submission planning and documentation strategy
- Identifying product-specific evidence requirements
- 02
Product and formulation documentation
- Product composition and ingredient documentation
- Product description and specifications
- Nicotine content and relevant product characteristics
- Manufacturing process documentation
- Product formulation and supporting technical information
- 03
Scientific and technical documentation
- Organising available toxicological evidence
- Review and coordination of relevant non-clinical and clinical evidence
- Product chemistry and emissions documentation, where applicable
- Review of health-risk investigation documentation
- Organising population-level health impact evidence
- 04
Manufacturing and quality documentation
- Manufacturing process descriptions
- Quality control documentation
- Product specifications and testing information
- Manufacturing facility and process-related documentation
- Supporting quality and compliance records
- 05
PMTA dossier preparation and submission
- PMTA dossier planning and compilation
- Review of administrative and scientific documentation
- Preparation and organisation of submission components
- Support for applicable FDA forms and electronic submission requirements
- Documentation quality and consistency review
- 06
TPMF support
- Tobacco Product Master File documentation support
- Preparation and review of relevant technical information
- Maintaining organised technical documentation
- Assistance with applicable cross-referencing requirements
- 07
FDA queries, deficiencies and post-submission
- Review of FDA deficiency communications
- Preparation and coordination of technical responses
- Support with amendments and additional information requests
- Documentation for applicable supplemental submissions and resubmissions
- Post-market regulatory documentation support, where applicable
How VERA 2.0 supports this sector
A PMTA must document how the product is manufactured and controlled. VERA 2.0 gives nicotine and tobacco product manufacturers continuous visibility into the conditions that influence product consistency.
- VERA 2.0
Manufacturing process visibility
Monitoring of selected process and equipment conditions that influence product consistency, where supported by connected systems.
- VERA 2.0
Quality control context
Anomaly identification highlights abnormal conditions early, supporting quality control and investigation by authorised personnel.
- VERA 2.0
Documented manufacturing history
Structured records of events and observations support the manufacturing and quality documentation a submission relies on.
- VERA 2.0
Post-authorisation consistency
Ongoing visibility into manufacturing conditions supports consistency after a marketing order is granted.
VERA 2.0 is an advisory decision-support system. It does not write to or control plant systems, and it does not replace the site’s quality management system, validated records or regulatory determinations. Capabilities depend on the systems connected at each site.
Get started with RIAR Consulting
Whether you are preparing a new PMTA, responding to FDA deficiencies or planning future product authorisations, RIAR Consulting can support your regulatory objectives.